Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13315213 | 1.00 | HTR3A (0.45) | HTR3AHTR4BTKGAAEPHX2 | |
| SCHEMBL22233663 | 1.00 | HTR3A (0.45) | HTR3AHTR4BTKGAAEPHX2 | |
| SCHEMBL16095456 | 1.00 | HTR3A (0.45) | HTR3AHTR4BTKGAAEPHX2 | |
| SCHEMBL13352069 | 1.00 | HTR3A (0.45) | HTR3AHTR4BTKGAAEPHX2 | |
| SCHEMBL19918949 | 1.00 | HTR3A (0.45) | HTR3AHTR4BTKGAAEPHX2 | |
| SCHEMBL10113719 | 1.00 | HTR3A (0.45) | HTR3AHTR4BTKGAAEPHX2 | |
| SCHEMBL12135068 | 1.00 | HTR3A (0.45) | HTR3AHTR4BTKGAAEPHX2 | |
| Oxalic Acid SCHEMBL30381775 | 0.96 | HTR3A (0.42) | HTR3AHTR4BTKGAAEPHX2 | |
| Oxalic Acid SCHEMBL31213543 | 0.96 | HTR3A (0.42) | HTR3AHTR4BTKGAAEPHX2 | |
| SCHEMBL25145140 | 0.88 | BTK (0.38) | HTR3AHTR4BTKGAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138204-B2 | Emesis, dyspepsia, gastroparesis, constipation, gastroesophageal reflux, or post-operative ileus; cisapride analogs; side effect reduction of adverse events; (R)-quinuclidin-3-yl 6-((3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate or salts | ARYX THERAPEUTICS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-1704146-B1 | STEREOISOMERIC COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7629466-B2 | Synthetic methods and intermediates for steroisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090137810-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085921-A1 | Stereoisomeric Compounds And Methods For The Treatment Of Gastrointestinal And Central Nervous System Disorders | ARYX THERAPEUTICS (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080076927-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7326787-B2 | Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7282509-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070078265-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007028073-A2 | SYNTHETIC METHODS AND INTERMEDIATES FOR STEREOISOMERIC COMPOUNDS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-7176218-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2007-02-13 | — | — | US | disclosed |
| WO-2007005951-A2 | STEREOISOMERIC PYRIDYL AND PYRIDONYL COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085921-A1 | Stereoisomeric Compounds And Methods For The Treatment Of Gastrointestinal And Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR3A 315/4885HTR4 70/4885BTK 3159/4885 |
| US-20080076927-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR3A 543/4885HTR4 193/4885BTK 3961/4885 |
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | CCKBR, HRH2, GRPR | HTR3A 282/4885HTR4 71/4885BTK 3029/4885 |
| US-20090137810-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR3A 543/4885HTR4 193/4885BTK 3961/4885 |
| US-20070078265-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR3A 543/4885HTR4 193/4885BTK 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.